Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174668
Title: | SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) |
Author: | Nadal, Ernest Bosch Barrera, Joaquim Cedrés, S. Coves, J. García Campelo, R. Guirado, M. López Castro, Rafael Ortega, A. L. Vicente, D. Castro Carpeño, Javier de |
Keywords: | Mesotelioma Protocols clínics Diagnòstic Mesothelioma Medical protocols Diagnosis |
Issue Date: | 4-Feb-2021 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future. |
Note: | Reproducció del document publicat a: https://doi.org/10.1007/s12094-020-02532-2 |
It is part of: | Clinical and Translational Oncology, 2021, Vol. 23, num.5, p. 980-987 |
URI: | http://hdl.handle.net/2445/174668 |
Related resource: | https://doi.org/10.1007/s12094-020-02532-2 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Nadal2021_Article_SEOMClinicalGuidelinesForTheTr.pdf | 582.56 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License